VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnershipstocktwits.comRaymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?stocktwits.comThe company said its current resources are expected to fund operations into the second quarter of 2028.
Is Alnylam Pharmaceuticals a Millionaire Maker?fool.comThis hot biotech stock could have a lot more room to run.
